

Ronald DeMatteo
Ronald DeMatteo: From an Italian Immigrant’s Legacy to the Frontiers of Cancer Research
The grandson of an Abruzzo villager, Penn’s Chair of Surgery helped turn a once-deadly cancer into a treatable disease, and he says he won’t retire until he cures it.
When Ronald DeMatteo talks about his grandfather, he remembers a man with whom he could barely communicate. His grandfather, Dominic DeMatteo, spoke Italian, never learned English despite spending some 50 years in the United States, and came from a small mountain village in Abruzzo. The young Ronald, who did not yet speak Italian, had found his own way of getting along with him: he would smile, his grandfather would offer him something to eat, and he would smile again. More food would follow.
Today, he is one of the leading surgical oncologists in the United States, a researcher whose work has helped transform the treatment of a rare form of cancer, and chair of the Department of Surgery at the University of Pennsylvania’s Perelman School of Medicine, the oldest department of surgery in the country.
For more than 25 years DeMatteo - recently awarded the 2026 Prize for Scientific Excellence in Medicine by the American-Italian Cancer Foundation - has devoted much of his research to gastrointestinal stromal tumors, or GISTs, the most common type of human soft tissue sarcoma. When he first became interested in the disease in the late 1990s, it was largely neglected. Diagnoses were inconsistent, little was known about its biology and, most importantly, there was no effective drug treatment.
A retrospective study he conducted while completing his surgical oncology training at Memorial Sloan Kettering Cancer Center in New York revealed the scale of the problem. Looking at patients who had undergone surgery to remove what appeared to be a single, localized tumor, he found that half had died within five years.
The finding became a turning point. DeMatteo became involved in developing clinical trials to test a new approach, using Imatinib, a targeted drug that blocks the molecular signals driving the tumor’s growth.
He led one of the two pivotal national trials launched in 1999, investigating whether the drug could prevent recurrence after surgery. The results led to FDA approval of Imatinib as an adjuvant treatment and helped establish a new international standard of care.
The difference has been dramatic. Patients who once faced a very poor prognosis can now live five, ten or even fifteen years longer. But DeMatteo is not ready to declare victory. Although five drugs are now FDA-approved for GIST, none can reliably eliminate the disease. His laboratory continues to investigate its biology, in the hope of identifying new therapeutic targets.
“We don’t usually see big changes like that in treating specific cancers,” he says. “But for this tumor, it’s night and day compared to what it used to be.”
At Penn, DeMatteo leads a department with a history stretching back to 1765. Its scale reflects its international standing: around 150 surgeons and an equal number of surgical trainees, with approximately 1,800 applicants competing for just nine places in its general surgery residency program.
For him, however, leadership is not simply about institutional prestige. It is about continuing to operate, training the next generation and sustaining a research commitment alongside an exceptionally demanding clinical schedule. His research has received continuous National Institutes of Health funding for more than 25 years.
Asked what kind of legacy he hopes to leave, he says: “I’d like to leave the legacy of being a very busy clinician and treating patients. That’s what we all went into surgery for.” Teaching, he adds, is equally important, “a big part of my life.”
There is another story behind that work ethic, one that takes him back across the Atlantic.
His grandfather left Pizzoferrato, and when he arrived at Ellis Island, he was sent to Pittsburgh, Pennsylvania, where he settled in Bloomfield, an Italian-American neighborhood so close-knit that he never needed to learn English.
In 1995, DeMatteo and his wife went to the village during their honeymoon in Italy. With no smartphones or GPS to guide them, they rented a car in Rome, consulted a map and set off in search of a place they had never seen.
They got lost, stopped at a Carabinieri station and asked for directions. One officer had never heard of the village. Another recognized the name and offered to escort them. Once they arrived, the only man in town who spoke English, who had known his grandfather, made a few calls from the bar’s payphone, and the village organized a feast that lasted from late afternoon until midnight. DeMatteo met his grandfather’s only surviving sister, then 91, and heard the story of his family’s departure firsthand. It was, he says, a remarkable day.
His own father had taken a different path. Born in America, he initially faced resistance to the idea of going to college: he nevertheless earned a business degree and became president of a large hospital in New Jersey. DeMatteo is only the second person in his family to have attended college.
His father had also wanted to leave behind the immigrant identity and become fully American. DeMatteo, by contrast, has embraced those roots. He studied Italian in New York and has passed on part of that heritage to his two daughters, Sienna and Alessia.
For DeMatteo, the link between his family’s past and his professional life is more than a matter of ancestry. He believes he has inherited what he calls the immigrant philosophy of work ethic: the determination to make the most of opportunities that previous generations had to struggle to create.
That philosophy continues to drive him. He still operates, treats patients and spends long hours in the laboratory, with no intention of slowing down. “I kind of joke that I’m not going to retire until I cure this disease,” he says. “In some ways I mean that, and I hope for that.”










